It will soon be time to process spring-born calves, which brings up the topic of best management practices and following Beef ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO ...
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results